Hepatitis C in HIV-Infected Patients: Impact of Direct-Acting Antivirals

Bichoupan, Kian; Dieterich, Douglas
June 2014
Drugs;Jun2014, Vol. 74 Issue 9, p951
Academic Journal
Approximately 30 % of HIV-infected patients are co-infected with hepatitis C virus (HCV). After the release of highly active antiretroviral therapy, liver disease has become the leading cause of morbidity and mortality in HIV patients. Prior to 2011, HCV treatment with pegylated-interferon and ribavirin in HCV/HIV co-infected patients only allowed 14-38 % of patients with HCV genotype 1 to achieve a sustained virologic response (SVR). Additionally, treatment was commonly discontinued as a result of adverse events. Recently, simeprevir and sofosbuvir have been approved by the US Food and Drug Administration (FDA) for HCV mono-infection. Sofosbuvir has been given FDA approval in co-infected patients offering unprecedented SVR rates and the potential for interferon-free therapy. HCV therapies that are in the pipeline offer improved treatment times, safety profiles, and rates of SVR. Despite these improvements, several new issues including adherence, drug-drug interactions with antiretroviral therapies, adverse events, resistance, and patient selection may complicate therapy. This article reviews the current status of direct-acting antivirals (DAA)-containing regimens for HIV/HCV co-infected patients in the USA. New results investigating telaprevir and boceprevir are also discussed as they are relevant for locations where new DAAs are not available. The impact future interferon-free therapies may have on co-infected patients is also discussed.


Related Articles

  • Treatment of Hepatitis C in HIV-Infected Patients: Moving Towards an Era of All Oral Regimens. Chen, Ting-Yi; Jain, Mamta K. // AIDS Patient Care & STDs;Jun2015, Vol. 29 Issue 6, p329 

    Hepatitis C (HCV)-related liver disease has become one of the leading causes of death in HIV patients. With the development of new direct-acting antivirals for HCV, treatment regimens have become shorter, more effective, and easier to tolerate without interferon. However, cost may be a...

  • Sofosbuvir Has Come Out of the Magic Box. Alavian, Seyed Moayed // Hepatitis Monthly;Dec2013, Vol. 13 Issue 12, p1 

    The editor discusses the discovery of Sofosbuvir as a drug that helps in eradication of hepatitis C Virus (HCV) infection. Topics discussed include Sofosbuvir approved by the U.S Food and Drug Administration advisory board for the treatment of chronic hepatitis C patients, a research, in which...

  • Daclatasvir + Asunaprevir: First Global Approval. Poole, Raewyn // Drugs;Sep2014, Vol. 74 Issue 13, p1559 

    The combination of daclatasvir + asunaprevir [Daklinza + Sunvepra (Japan)], two direct-acting antiviral agents, has been developed by Bristol-Myers Squibb for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1 infections, including those with compensated cirrhosis....

  • Gilead's Sofosbuvir Expected to Sail Through Panel Meeting. Shaffer, Catherine // BioWorld Today;10/24/2013, Vol. 24 Issue 205, p1 

    The article reports on the U.S. Food and Drug Administration (FDA) Antiviral Drugs Advisory Committee's scheduled discussion approval of sofosbuvir in hepatitis C virus (HCV). The discussion will be focused on the optimal duration of therapy in genotype 2 and 3 patients. An overview of the data...

  • FDA panel OKs new class of HIV drug. Roehr, Bob // Bay Area Reporter;4/26/2007, Vol. 37 Issue 17, p17 

    The article reports that a committee of the U.S. Food and Drug Administration has recommended approval of Pfizer Inc.'s CCR5 inhibitor maraviroc, trademarked Celsentri. Maraviroc belongs to a class of anti-HIV drugs developed for heavily treatment-experienced patients. It works against the R5...

  • Enfuvirtide. Coleman, Craig I.; Musial, Bogdan L.; Ross, Jack // Formulary;Apr2003, Vol. 38 Issue 4, p204 

    Focuses on enfuvirtide, the first member of antiretrovirals to gain U.S. Food and Drug approval for the treatment of HIV-1 infection. Pharmacology; Pharmacokinetics; Clinical trials of enfuvirtide; Safety and tolerability; Drug interactions; Dosage and administration; Cost. INSET: Formulary...

  • Sofosbuvir: First Global Approval. Keating, Gillian; Vaidya, Asha // Drugs;Feb2014, Vol. 74 Issue 2, p273 

    Sofosbuvir (Solvadiâ„¢), a nucleotide analogue hepatitis C virus NS5B polymerase inhibitor, is under development with Gilead Sciences for the once-daily, oral treatment of chronic hepatitis C. Oral sofosbuvir has been approved in the US for the treatment of chronic hepatitis C as a component...

  • Merck, Vertex Hep C Drugs Are Likely Scene Changers. Serebrov, Mari // BioWorld Today;4/26/2011, Vol. 22 Issue 80, p1 

    The article reports that a new class of drugs for hepatitis C virus (HCV) therapies from Merck & Co. Inc. and Vertex Pharmaceuticals Inc. is expected to change the market. Boceprevir from Merck and telaprevir from Vertex will be presented to the Antiviral Drugs Advisory Committee of the U.S....

  • One-day, one-dose herpes treatments OK'd.  // Drug Topics;8/21/2006, Vol. 150 Issue 16, p8 

    The article reports that the drug Faciclovir has been approved in the U.S. as a single-day treatment for recurrent genital herpes and as a single-dose treatment for recurrent herpes labialis, both in immunocompetent patients. It was stated that this marks the first time an intiviral has been...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics